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Autoimmune hemolytic anemia (AIHA) is a recognized complication of hematopoietic stem cell trans-
plantation (HSCT); it is often refractory to treatment and carries a high mortality. To improve understanding
of the incidence, risk factors, and clinical outcome of post-transplantation AIHA, we analyzed 533 patients
who received allogeneic HSCT, and we identiﬁed 19 cases of AIHA after HSCT (overall incidence, 3.6%). The
median time to onset, from HSCT to AIHA, was 202 days. AIHA was associated with HSCT from unrelated
donors (hazard ratio [HR], 5.28; 95% conﬁdence interval [CI], 1.22 to 22.9; P ¼ .026). In the majority (14 of 19;
74%) of AIHA patients, multiple agents for treatment were required, with only 9 of 19 (47%) patients achieving
complete resolution of AIHA. Patients with post-transplantation AIHA had a higher overall mortality (HR,
2.48; 95% CI, 1.33 to 4.63; P ¼ .004), with 36% (4 of 11 cases) of deaths attributable to AIHA.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
The development of autoimmune diseases is an increas-
ingly recognized complication after hematopoietic stem cell
transplantation (HSCT) [1]. Depending on the type of HSCT,
the effector lymphocytes can either be autologous or
allogeneic in origin. After autologous HSCT, autoreactive
lymphocytes targeting “self” tissue can lead to a range of
autoimmune diseases affecting the hematological, endo-
crine, and neurological systems, as well as connective tissues.
After allogeneic HSCT, autoimmunity speciﬁcally refers to
allogeneic lymphocytes that target donor-derived tissue, eg,
autoimmune cytopenia, or well-recognized autoantigens not
speciﬁc to the donor or recipient, for instance, acetylcholine
receptor in myasthenia gravis. Among autoimmune condi-
tions that develop after HSCT, autoimmune hemolytic
anemia (AIHA) is the most frequently reported [1-3].edgments on page 66.
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ty for Blood and Marrow Transplantation.Current estimates of the incidence of AIHA after HSCT are
between 2% to 6%, affecting both adult [4-9] and pediatric
[2,3,10,11] patients. Higher incidences of up to 15% to 20%
have been reported [12,13], albeit in speciﬁc clinical settings
and with less conventional conditioning regimens. The
median time of onset of AIHA has been observed to be be-
tween 5 and 12months after HSCT [2-8,10]. Hemolysis can be
mediated by cold (IgM) or warm (IgG) autoantibodies, which
has been suggested to correlatewith early or late onset AIHA,
respectively, reﬂecting the process of B lymphocyte switch
from IgM to IgG production during immune reconstitution
after HSCT [5].
Development of AIHA after HSCT has been associated
with HSCT from unrelated donors and concurrent chronic
graft-versus-host disease (GVHD) [6,9], suggesting a role for
mismatched antigens in the pathogenesis of AIHA after
allogeneic HSCT. Lymphocyte depletion of the donor graft
with ex vivo lymphodepletion [12] or in vivo lymphodeple-
tion using antithymocyte globulin (ATG) or alemtuzumab
[7,8] have also been associated with AIHA, possibly through
removal of CD4þ CD25þ regulatory T cells, thus favoring the
expansion of autoreactive lymphocytes [14]. Other reported
Table 1
Transplantation Characteristics of HSCT Recipients and Patients Developing
Post-Transplantation AIHA
Characteristic Total AIHA, n (%) P Value
No. of HSCTs 533 19 (3.6)
Sex
M 323 14 (4.3) .23
F 210 5 (2.4)
Age at HSCT, average, yr 49 48
Diagnosis
AML 204 6 (2.9) NS
MDS 112 5 (4.5)
NHL 63 2 (3.2)
AA 47 2 (4.3)
ALL 25 0
CML 24 2 (8.3)
CLL 19 2 (10.5)
MPD 12 0
HL 10 0
MM 7 0
Others 10 0
HSCT type
UD 352 17 (4.8) .03
Sibling 181 2 (1.1)
Source of stem cells
Peripheral blood 446 16 (3.6) .44
Bone marrow 52 3 (5.8)
Cord 26 0
 9 0
Condition regimen
Alemtuzumab/ATG 422 17 (4.0) .26
Non-alemtuzumab/ATG 111 2 (1.8)
RIC 473 17 (3.6) .92
Myeloablative 60 2 (3.3)
HLA mismatch
0 417 15 (3.6) .37
1 68 4 (5.9)
2 21 0
>2 19 0
 8 0
ABO mismatch
No 251 7 (2.8) NS
Major 111 3 (2.7)
Minor 122 7 (5.7)
Bidirectional 41 2 (4.9)
ND 8 0
Sex mismatch
No 302 16 (5.3) .02
Mismatch 207 3 (1.4)
 24 0
Recipient CMV Status
Positive 272 9 (3.3) .60
Negative 238 10 (4.2)
 23 0
Chronic GVHD
Yes 142 8 (5.6) .20
No 358 11 (3.1)
 33 0
M indicates male; F, female; AML, acute myeloid leukemia; NS, not signiﬁ-
cant; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; AA,
aplastic anemia; ALL, acute lymphoid leukemia; CML, chronic myeloid
leukemia; CLL, chronic lymphoid leukemia; MPD, myeloproliferative
disease; HL, Hodgkin lymphoma; MM, multiple myeloma; RIC, reduced-
intensity conditioning.
A dash indicates that data are not available.
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HSCT for treatment of nonmalignant diseases [2,3,10], being
younger at transplantation [10], receiving HSCT from
peripheral blood stem cells [12], and having a short interval
from diagnosis of disease to HSCT treatment [2]. The clinical
signiﬁcance of these risk factors remains uncertain, as they
have not been consistently reported among studies.
Despite the multitude of immunosuppressive therapies
used for treatment, the clinical outcome of AIHA after HSCT isvariable [1,2]. Currently, there is no consensus regarding the
optimal therapeutic approach. Whether AIHA contributes to
increasedmortality is equally controversial. Although certain
studies have observed mortality of up to 50% in patients with
AIHA after allogeneic HSCT [6,10], others have reportedmuch
lower mortality in children [3], and no increase in mortality
was attributed to secondary autoimmune diseases after
autologous [8] or cord blood HSCT [2]. At present, mortality
data are lacking for adult populations undergoing HSCT for
malignant diseases, the largest patient population undergo-
ing transplantation. To better understand the risk factors,
prognosis, and management of post-HSCT AIHA, we carried
out a retrospective analysis of 533 allogeneic HSCTs per-
formed at King’s College Hospital between 2005 and 2011.
MATERIALS AND METHODS
Patients
Between January 2005 and November 2011, 533 allogeneic HSCTs car-
ried out at King’s College Hospital (London, UK) were included in the study.
In patients who received more than 1 HSCT, each transplantation was
counted as a separate event if the graft was received from a different donor,
and the transplantations were counted as the same event if the graft was
received from the same donor. The median follow-up period after HSCT was
31 months (range, 2.9 to 100 months).
Transplantations Protocols
The transplantation protocols were approved by the local research
ethics committee and informed consent was obtained from all patients.
Human leukocyte antigen (HLA) typing of recipients and donors was carried
out by high-resolutionmolecular techniques. Patients with an HLA-matched
sibling donor received the graft from the sibling; otherwise, a suitable un-
related donor (UD) was identiﬁed. The selection of conditioning regimen
and source of hematopoietic stem cells were based on hematological diag-
nosis, donor availability, and clinical state of the patient. GVHD prophylaxis
for standard conditioning regimens consisted of methotrexate with cyclo-
sporine administered for a minimum of 6 months and tapered thereafter. In
reduced-intensity conditioning regimens, the only GVHD prophylaxis was
cyclosporine, administered from day 1 and tapered from day þ56 in the
absence of GVHD. Granulocyte-colony stimulating factor (Granocyte,
263 mg/day, Chugai Pharma, London, UK; or Neupogen 300 mg/day, AMGEN,
Thousand Oaks, CA) was administered subcutaneously or intravenously
from day þ7 until stable neutrophil engraftment. Chimerism analysis was
performed routinely on days þ28, þ56, þ100, then 6 months after HSCT
using single nucleotide polymorphism analysis. Red cells and platelets were
transfused to maintain hemoglobin level and platelet count above 80 g/L
and 10  109/L, respectively. All cellular blood products in the United
Kingdom (except granulocytes) are leukodepleted at source by ﬁltration. All
patients received antiviral and antifungal prophylaxis using aciclovir and a
triazole agent. Prophylaxis with azithromycin was given to donors or re-
cipients with serological evidence of toxoplasma exposure. All patients were
monitored weekly for cytomegalovirus (CMV), Epstein-Barr virus, and
adenovirus DNA. The conditioning regimen and transplantation character-
istics of our patients are shown in Table 1.
Deﬁnitions
AIHA was deﬁned by positive direct agglutinin test (DAT) arising after
the HSCT, with biochemical markers of hemolysis (raised serum lactate
dehydrogenase, reduced haptoglobin, or spherocytes on the blood ﬁlm).
Hemolysis was considered signiﬁcant if the drop in hemoglobin was 20 g/
L. Cases of DAT positivity due to ABO antibodies, as well as thosewith history
of AIHA or positive DAT before HSCT, were excluded. DAT was performed in
selected patients after HSCT with appropriate clinical indications. Patients
who never had DAT were presumed not to have clinically signiﬁcant AIHA.
Patients with positive DAT but evidence of nonimmune hemolysis, eg,
microangiopathic hemolytic anemia, were also excluded. Onset of AIHAwas
calculated from the ﬁrst documented detection of AIHA by either clinical
symptoms or positive DAT. Resolution of AIHA was deﬁned as normalization
of hemoglobin and biochemical markers of hemolysis and independence
from additional treatment. Partial response to treatment for AIHA was
deﬁned as an improvement in markers of hemolysis with requirement of
maintenance treatment. Included within the partial response group were 2
patients who suffered relapse of their primary hematological disease,
resulting in withdrawal of treatment for AIHA, and 2 additional patients
who died of non-AIHAerelated causes while receiving treatment for AIHA.
Refractory AIHAwas deﬁned as failure to respond after 4 or more modalities
Clinically Significant Hemolysis
533 Allogeneic HSCTs
(01/2005 – 11/2011)
DAT after HSCT
275 (51%)
Biochemical Markers of Hemolysis
DAT+
109 (20%)
DAT–
166 (31%)
Yes
39 (7%)
No
70 (13%)
Yes
22 (4%)
No
17 (3%)
AIHA
19 (3.6%)
Alloimmune
3 (<1%)
Figure 1. Identiﬁcation of AIHA from 533 allogeneic HSCTs.
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therapies (cyclosporine, mycophenolate mofetil, azathioprine, and siroli-
mus) or surgical splenectomy.
Serology
All recipients and donors had ABO and Rh blood group typing (forward
and reverse) performed on DiaMed gel columns. Antibody screening was
performed by indirect antiglobulin test against a 3-cell panel (DiaMed,
Cressier, Switzerland); antibody identiﬁcation was performed against a
panel of 10 cells. DAT was performed on DiaMed gel columns. The presence
of IgG and C3d on red cells was demonstrated by testing with monospeciﬁcTable 2
Clinical Characteristics of Patients with AIHA
Case No. Diagnosis Sex Age at HSCT HSCT Type
Donor Regimen R
1 AML F 42 UD FBC R
2 MCL M 59 UD BEAM C R
3 AML M 46 Sibling FCC R
4 MDS M 28 UD FluATG R
5 AA M 37 UD FCC R
6 CML M 49 UD FBC R
7 AML F 65 UD FBC R
8 AA M 21 UD FCC TBI R
9 CLL M 60 UD FMC R
10 AML F 43 UD FBC R
11 MDS F 54 UD FBC R
12 CML M 34 UD BU CY TBI M
13 AML M 33 UD BU CY TBI M
14 MDS M 58 UD FBC R
15 AML M 62 UD FBC R
16 CLL M 51 UD FMC R
17 MDS F 67 UD FBC R
18 MDS F 44 UD FBC R
19 NHL M 46 Sibling BEAM C R
MA indicates myeloablative; UF, unfractionated; FBC, ﬂudarabine/busulfan/alemtuz
FCC, ﬂudarabine/cyclophosphamide/alemtuzumab; Flu, ﬂudarabine; TBI, total bod
cyclophosphamide.
A dash indicates that data are not available.reagents at 37C. Red cellebound antibodies were eluted by acid elution
(Gamma Elu-kit, Immucor, Norcross, GA).
Statistical Analysis
The primary endpoint was the onset of AIHA. Potential risk factors for
development of AIHAwere calculated initially with univariate comparisons of
incidence of AIHA for each clinical strata using chi-squared test. All P values
were 2 sided and considered signiﬁcant if <.05. The following variables were
included in univariate analysis for risk factors: recipient gender, primary
hematological disease, HSCT type (unrelated versus sibling), source of stem
cells (peripheral blood versus bone marrow versus cord), conditioning
regimen (alemtuzumab/ATG versus non-alemtuzumab/ATG, and reduced
intensity versus myeloablative), HLA mismatch between donor and recipient,
ABO antigen mismatch, gender mismatch between donor and recipient,
recipient CMV status, and concurrent chronic GVHD. Chronic GVHD was
modeled as a time-dependent variable, whereas all other variables were
modeled as categorical variables. Risk factors achieving statistical signiﬁcance
on univariate analysis underwent additional multivariate analysis with Cox
regression to identify the most signiﬁcant independent risk factors.
The secondary endpoint was mortality. The Cox regression proportional
hazard model was used to compare mortality caused by AIHA against overall
mortality and transplantation-related mortality. As the onset of AIHA varied
over time after HSCT, AIHAwas modeled as a time-dependent variable when
estimating mortality. All patients alive at last follow-up who did not develop
AIHAwere censored. SPSS Statistics (IBMSPSSStatistics forMacintosh, Version
21.0; IBM Corp., Armonk, NY) software was used for all statistical analysis.
RESULTS
Identiﬁcation of AIHA after Allogeneic HSCT
Records of 533 HSCT patients were analyzed for evidence
of AIHA (Figure 1, Table 1). Of the 279 patients who had a DAT
after HSCT, 109 patients tested DAT positive. Thirty-nine of
109 cases (7% of the total number of patients) had a positive
DAT and positive biochemical markers of hemolysis, but only
19 of these cases exhibited clinically signiﬁcant hemolysis to
be classiﬁed as AIHA, resulting in an overall incidence of 3.6%
(Figure 1). In the other 20 cases with positive DAT and
biochemical markers of hemolysis, 3 cases exhibited
alloimmune hemolysis, whereas the remaining 17 cases did
not exhibit clinically signiﬁcant hemolysis.
Clinical characteristics of the AIHA cases are summarized
in Table 2. The median time to onset of AIHA after HSCT was
202 days (Figure 2). In 3 cases, onset of AIHA was precededTime to AIHA, d Chronic GVHD Peripheral Blood
Chimerism
IC/MA
UF CD3 CD15
IC 121 Yes 100 100 100
IC 131 Nil 95 95 100
IC 135 Nil 100 86 100
IC 144 Yes 98 100 100
IC 175 Nil 99 82 100
IC 180 Yes - - -
IC 183 Yes 99 77 99
IC 187 Yes 100 100 -
IC 193 Yes 100 98 100
IC 202 Yes 95 96 100
IC 204 Nil 81 27 83
A 209 Nil 100 - -
A 220 Nil 100 - -
IC 220 Yes 100 - -
IC 253 Nil 72 5 82
IC 315 Nil 100 100 100
IC 340 Nil 99 82 100
IC 378 Nil 100 - -
IC 569 Nil 100 82 100
umab; BEAM C, carmustine/cytarabine/etoposide/melphalan/alemtuzumab;
y irradiation; FMC, ﬂudarabine/melphalan/alemtuzumab; BU, busulfan; CY,
Figure 2. Event plot showing days since HSCT until the onset of clinically
detectable AIHA.
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and pneumonia of undetermined etiology). At the onset of
AIHA, one half of the patients were receiving immunosup-
pressive therapies, either as GVHD treatment or prophylaxis.
Unfractionated peripheral blood, CD3, and CD15 chimerism
were tested within 1 month of onset of AIHA in 18 of 19
patients; of those, 16 had 95% to 100% unfractionated pe-
ripheral blood donor chimerism, with 77% to 100% CD3/CD15
chimerism (Table 2). Case 11 had 81% unfractionated pe-
ripheral blood donor chimerism at onset of AIHA and had
concurrent relapse of MDS. Case 15 had 72% unfractionated
peripheral blood chimerism at onset of AIHA. In both cases,Figure 3. Serology investigations of AIHA patients. (A) Results of DAT, antibody speciﬁ
and recipient. (B) Number of cases with antibodies identiﬁed in the serum in AIHA pop
globulin test. (C) Red cell units transfused in AIHA patients between the HSCT to the o
over a similar time period. Average red cell units transfused as indicated. Pan indicatwhere mixed donor/recipient chimerism was present, we
cannot exclude the possibility that a recipient-versus-donor
alloimmune hemolysis could have contributed to the
immune-mediated hemolysis.
Risk Factors for AIHA
Transplantation characteristics were compared between
allogeneic HSCT recipients without AIHA and those who
developed AIHA after HSCT (Table 1). Univariate analysis
showed that AIHAwas signiﬁcantly associatedwithHSCT from
anunrelateddonor (UD4.8%versus sibling donor 1.1%, P¼ .03),
and concordant gender between the donor and the recipient
(no gender mismatch 5.3% versus gender mismatch 1.4%,
P ¼ .02). Multivariate analysis using Cox regression model
showed that HSCT from UD remained statistically signiﬁcant
(P¼ .026; hazard ratio [HR], 5.28; 95% conﬁdence interval [CI],
1.22 to 22.9), whereas concordant gender was of borderline
signiﬁcance (P ¼ .045; HR, 3.52; 95% CI, 1.03 to 12.1). No sig-
niﬁcant association was observed between AIHA and the
following variables: recipient gender, primary hematological
disease, source of hematopoietic stem cells, conditioning
regimen (alemtuzumab/ATG versus non-alemtuzumab/ATG,
and reduced intensity versus myeloablative), HLA mismatch
betweendonorand recipient,ABOantigenmismatch, recipient
CMV status, and concurrent chronic GVHD.
Serological Analysis of AIHA Patients
In 18 of 19 cases, IgG antibodies were present on red
cells, with 15 of 18 also being positive for C3d (Figure 3A).
Serological details of the positive DAT for case 9 were not
available. Elution studies were performed in 7 patients:
panreactive antibodies were detected in 6 of 7 eluates, but
only 1 of 7 eluates contained an anti-Rh antibody (anti-e),
likely to be an autoantibody as the patient (number 13) alsocities from the serum, and red cell elution studies and blood group of the donor
ulation compared with HSCT population that tested negative in the direct anti-
nset of AIHA, compared with DAT-negative patients who received transfusions
es panreactive; ND, not detected; , data not available.
Table 3
Clinical Course for Patients with AIHA
Case No. Treatment Clinical Outcome
1 Prednisolone, rituximab, cyclosporine Resolved.
2 Prednisolone Resolved.
3 Prednisolone, IVIg, rituximab, azathioprine, danazol AIHA controlled with maintenance prednisolone and danazol.
4 Prednisolone, rituximab Resolved. Died (relapsed MDS).
5 Prednisolone Resolved
6 Prednisolone, rituximab, cyclosporine, splenectomy Refractory AIHA. Died (AIHA).
7 Prednisolone, IVIg, rituximab Resolved.
8 Prednisolone, rituximab, plasma exchange, splenectomy Refractory AIHA. Died (AIHA and sepsis).
9 Prednisolone AIHA initially resolved with treatment. Died (relapsed CLL with AIHA).
10 Prednisolone, IVIg, cyclosporine AIHA responded to treatment but stopped due to relapsed AML. Died
(AML relapse).
11 Prednisolone AIHA responded to prednisolone but stopped due to MDS relapse. Died
(MDS relapse).
12 IVIg Resolved.
13 Prednisolone, IVIg, rituximab, plasma exchange,
splenectomy, sirolimus
Refractory AIHA. Died (AIHA).
14 Prednisolone, IVIg, rituximab, cyclosporine AIHA responded to treatment. Died (while on reducing doses of prednisolone).
15 Prednisolone, rituximab Resolved. Died (sepsis and encephalopathy).
16 Prednisolone, IVIg, rituximab, cyclosporine, mycophenolate Resolved.
17 Prednisolone, rituximab AIHA responded to treatment. Died (while on reducing doses of prednisolone).
18 Prednisolone, IVIg, rituximab, mycophenolate Refractory AIHA. Died (sepsis, AIHA).
19 Prednisolone, rituximab Resolved.
The causes of death are shown in brackets under clinical outcome.
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braneebound antibodies, 11 patients had antibodies in the
serum: panreactive (auto) antibodies were present in 5,
whereas antibodies against Rh and Kell antigens were found
in the serum of all 11 patients (Figure 3A).
We postulate that Rh antibodies in the serum of 11
patients were donor-derived alloantibodies that remained
unbound to antigens on donor-derived red cells. In support
of this hypothesis, patients numbered 5 and 19, initially RhD
positive, received their graft from RhD-negative donors
(Figure 3A); they developed an anti-D after achieving
engraftment (unfractionated chimerism, 100%; CD3, 82%;
and CD15, 100%). Thus, these examples of anti-D were allo-
antibodies of donor origin, with immunization probably
occurring after exposure to RhD antigen on residual host
erythrocytes. Furthermore, anti-K detected in patient num-
ber 2 was also an alloantibody, as both the donor and
recipient had kk genotype; donor origin of the antibody is
implied because of a 100% donor chimerism at the time of
testing, whereas immunization probably occurred after
transfusion of a K-positive red cell unit.
We assessed whether the high frequency of alloanti-
bodies observed among the patients with AIHA was a com-
mon feature after HSCT by analyzing the patients who tested
negative for DAT (Figure 3B). We found that only 4% of pa-
tients with a negative DAT developed alloantibodies, in
contrast to 58% of patients with AIHA. To rule out the
possible bias due to higher transfusion rate of AIHA patients,
we compared the number of transfused red cell units over a
similar time period before the onset of AIHA between AIHA
cases and DAT-negative cases, and we observed no signiﬁ-
cant difference between these 2 groups (Figure 3C).
Treatment and Outcome
The majority of AIHA patients were treated with more
than 1 therapeutic agent; 5 of 19 patients (26%) received
single-agent therapy, 4 (21%) received 2 agents, and the
remaining 10 patients (53%) received 3 or more agents. The
speciﬁc course of treatment for each patient is shown in
Table 3. Prednisolone (starting dose 1 mg/kg) was used as
ﬁrst-line therapy in 18 cases, with rituximab in 13 cases assecond-line or third-line treatment (after a trial of intrave-
nous immunoglobulin [IVIg]). Treatments in addition to rit-
uximab were required in 8 cases; including combinations of
plasma exchange (2 cases); immunosuppressive agents
including cyclosporine, mycophenolate mofetil, azathio-
prine, and sirolimus (7 cases); and splenectomy (3 cases).
Overall, the response to treatment was variable. Complete
resolution of AIHA was achieved in 9 of 19 cases (47%). Of
these 9 cases, 1 resolved with IVIg alone, 2 with prednisolone
alone; 4 required the addition of rituximab and 2 required
rituximab with further immunosuppression (cyclosporine
and mycophenolate mofetil). Partial response was seen in 6 of
19 patients (32%), of whom 2 died of relapsed primary he-
matological disease during treatment, necessitating discon-
tinuation of immunosuppression. Two patients died of non-
AIHAerelated causes during AIHA treatment; 1 developed
relapsed AIHA after initial response and 1 required ongoing
maintenance steroids. Refractory AIHAwas observed in 4 of 19
cases (21%), including the 3 who underwent surgical sple-
nectomy that failed to control the hemolysis.
At the time of analysis, 9 of the 19 AIHA patients were
alive. The median survival from onset of AIHA was 487 days
(range, 26 to 1977 days). AIHA was a major cause to death in
4 patients: 2 died directly as a result of AIHA and in 2 other
cases, sepsis also contributed to death. Four patients died
because of disease relapse and 2 died while on prednisolone
treatment. To account for the late onset of AIHA after HSCT,
we used the Cox regression model to evaluate AIHA as a
time-dependent risk factor, whereby association between
mortality and AIHA is analyzed from the time of AIHA onset
rather than spanning the total follow-up period after HSCT.
Within this model, we tested additional variables that we
found earlier to be associated with AIHA (HSCT from unre-
lated donors, donor/recipient gender concordance) in a
multivariate analysis to exclude confounding factors inﬂu-
encing mortality (Table 4). The results indeed showed AIHA
to be the only risk factor associated with both increased
overall mortality (HR, 2.48; 95% CI, 1.33 to 4.63; P¼ .004) and
increased transplantation-related mortality (HR, 4.38; 95%
CI, 1.96 to 9.77; P < .001). Therefore, we conclude that pa-
tients who developed AIHA as a complication of HSCT has
Table 4
Cox RegressionMultivariate Analysis of Potential Risk Factors for Overall and
Transplantation-Related Mortality
Overall Mortality Transplantation-
Related Mortality
HR 95% CI P Value HR 95% CI P Value
AIHA 2.48 1.33-4.63 .004 4.38 1.96-9.77 <.001
Unrelated donor .94 .72-1.22 .63 .80 .55-1.18 .27
Gender concordance .88 .68-1.14 .32 .68 .48-.97 .03
AIHA was modeled as time-dependent variable; unrelated donor and
gender concordance (between donor/recipient) were modeled as time-
independent variables.
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tients who did not develop AIHA.DISCUSSION
In our single-center retrospective analysis of 533 adult
patients who underwent allogeneic HSCT, we report the
overall incidence of AIHA after HSCT is 3.6%. This is in
agreement with the previously reported incidence for com-
parable populations [4-6,9]. One study reported the inci-
dence of AIHA after HSCT to be as high as 15% in adult
patients with chronic myeloid leukemia treated with HSCT
[13]. However, the majority of the hemolysis cases coincided
with relapsed chronic myeloid leukemia and resolved with
donor lymphocyte infusion, suggesting the immune-
mediated hemolysis was not true AIHA but more likely
recipient-versus-donor alloimmune hemolysis. None of the
26 cord blood HSCTs developed AIHA, which likely reﬂects
the low number of cord HSCT performed at our center, where
only 12 of 26 patients survived beyond 202 days (median
onset for AIHA), combined with a reported incidence of AIHA
after cord HSCT to be only 5% to 6.6% [2,9].
Nearly two thirds of HSCT patients with a positive DAT
exhibited no biochemical or clinical evidence of hemolysis.
Nevertheless, 17 patients (3% of total HSCT analyzed) had
positive DAT with biochemical markers of hemolysis but
without signiﬁcant anemia (Figure 1). In 3 of 17 cases, there
was evidence of microangiopathic hemolytic anemia, which
could account for the positive markers of hemolysis with a
probable incidental positive DAT. However, we cannot
exclude the possibility that these patients had mild or
compensated AIHA, and that AIHA after HSCT could be more
common thanwe estimated, but in some cases the hemolysis
is transient or self-resolving with little clinical impact or
obscured by concurrent conditions.
Patients with the highest risk of developing AIHA were
those who received HSCT from unrelated donors, consistent
withresults fromotherstudies [2,3,6,10].Wehypothesizedthat
this reﬂected the donor immune system reacting to mis-
matched antigens of the recipient, similar to the pathogenesis
of GVHD. However, we did not observe an increased incidence
of AIHA inpatients receivingHSCT fromdonorsmismatched at
class I/II HLA antigens or ABO antigens. In addition, we
observed no association between AIHA and chronic GVHD, a
complication known tobe associatedwith increasingdegreeof
mismatch in HLA antigen between the donor and recipient.
Other studies in adult HSCT have identiﬁed chronic GVHD as a
risk factor for AIHA [6,9]; the disparity with our study may
simply reﬂect the overall low number of AIHA cases in the
studies, but it raises the possibility that the mechanism un-
derlyingAIHA isdistinct fromthatcausingGVHD. Inourpatient
cohort, asAIHAoccurredat thetimewhenmore than95%bloodcells were of donor origin, we speculate that aberrant immune
reconstitution of the donor HSCT within the foreign environ-
mentof the recipientmay favor theexpansionof autoreactiveB
cells. A possible mechanism could involve a delay in B cell re-
covery afterHSCT leading to high levels of circulating plasma B
cellactivating factor,whichhasbeenassociatedwithaberrantB
cell homeostasis [15-18].
Studies of autologous HSCT for treatment of autoimmune
diseases have identiﬁed intense lymphodepletion from using
conditioning regimens containing alemtuzumab/ATG [7,8] as
a risk factor for development of post-HSCT autoimmune
diseases. Our study along with others failed to support this
ﬁnding [2,3,6,10,12]. This discrepancy could reﬂect the
different indications for HSCT (malignant diseases versus
autoimmune diseases) and donor source of stem cells (allo-
geneic or autologous). However, as the majority of patients in
our study received alemtuzumab/ATG as part of the condi-
tioning (79%) with reduced-intensity conditioning regimens
(89%), this could have been a limiting factor in identifying
these variables as statistically signiﬁcant risk factors. We also
found concordant gender between the donor and recipient of
the HSCT to be weakly associated with the onset of AIHA,
although this will need further validation in future studies.
Warm-reacting panreactive autoantibodies were the most
frequently identiﬁed red cell antibodies in our study, in
agreement with other reports [5,6,10,12,13]. Chimerism
studies in our patients suggest that post-HSCT AIHA is a
“donor-against-donor” phenomenon; however, the exact role
of the host immune system, eg, antigen-presenting cells, is
poorly understood. Surprisingly, 58% AIHA patients also had
antibodies against Rh/Kell antigens which, as detailed in the
results section, appear to be alloantibodies. Chen et al. [5]
made a similar observation that anti-Rh antibodies were
found predominantly in the serum but not the eluates. An
alternative explanation could be that at least some of the
apparent alloantibodies were, in fact, red cell autoantibodies
that mimicked alloantibodies by their reactions. Issitt et al.
[19] found that nearly one half of apparent alloantibodies,
detected in patients with positive DAT and serum panag-
glutinins were autoantibodies that mimicked alloantibodies
with speciﬁcities within the Rh system. Association between
allo- and autoimmunization has been described in patients
requiring multiple blood transfusions [20-23]; however, there
was no signiﬁcant difference between the number of red cell
units transfused over a similar time period before AIHA onset
between the AIHA and non-AIHA population in our study. The
high frequency of alloimmunization in our patients may be a
result of the same defect in immune tolerance that underlies
AIHA.Murinemodels have implicated CD4þ CD25þ regulatory
T cells, whose depletion resulted in induction of both AIHA
[24] and alloimmunization [25].
Current evidence [2,6,10,26-29] suggests the AIHA that
develops after HSCT is more refractory to treatment
compared with primary AIHA, where themajority of patients
respond to steroids as ﬁrst-line therapy [30]. We report a
similar outcome in our study, where only 10% (2 of 19) of
AIHA patients were treated successfully with prednisolone
alone and 74% (14 of 19) required multiple therapeutic
agents. Although AIHA in patient number 12 resolved with
IVIg monotherapy, it is possible that the AIHA in this patient
was transient in nature and would have resolved without
additional treatment. The most effective treatment consisted
of rituximab in combination with prednisolone or other
immunosuppressive agents, which achieved resolution of
AIHA in 46% (6 of 13) of patients treated with this regimen.
M. Wang et al. / Biol Blood Marrow Transplant 21 (2015) 60e6666Other studies have noted similar efﬁcacy of rituximab in
treatment for post-HSCTAIHA [2,3,29]. Furthermore, a recent
randomized controlled trial suggested beneﬁt in using
prednisolone and rituximab together over prednisolone
alone as ﬁrst-line therapy in the treatment of primary AIHA
[31]. Taken together with our observations, there may be a
rationale for combination treatment containing rituximab as
ﬁrst-line therapy for post-HSCT AIHA.
The overall mortality rate for our AIHA patients was
high at 53% (10 of 19 cases), with AIHA as a cause of death
in 36% of deceased patients. Although higher than ex-
pected mortality has been previously observed in trans-
plantation patients who develop AIHA, evidence regarding
whether AIHA contributes to increased mortality in these
patients is lacking. We have shown that AIHA after HSCT
indeed results in an increased risk of mortality with over
2-fold higher overall mortality in the patients with AIHA
compared with those without. Our ﬁnding is in contrast
with 2 previous studies by Daikeler et al. [2,8] that re-
ported no mortality difference attributable to secondary
autoimmune complications after autologous or cord HSCT.
However, we note that in 1 of these studies [2] the major
cause of death (5 of 12 cases) was indeed secondary AIHA
or Evans syndrome (combination of AIHA and idiopathic
thrombocytopenic purpura). Thus, although Daikeler et al.
analyzed mortality for all autoimmune complications, we
focused solely on AIHA, which could have a worse clinical
outcome compared with other autoimmune diseases that
develop after HSCT.
In conclusion, AIHA is a late complication of allogeneic
HSCT that develops, on average, 202 days after trans-
plantation. Patients are at higher risk of developing AIHA if
they received HSCT from unrelated donors and potentially if
the donor and recipient are of the same gender. Post-HSCT
AIHA is frequently resistant to treatment and confers
decreased overall survival. Given the poor overall response
with single-agent therapy, prospective studies that explore
the beneﬁt of combination ﬁrst-line therapy with steroids
and rituximab are warranted.
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